{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:47:30Z","timestamp":1792601250072,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2314-B-006-090"],"award-info":[{"award-number":["NSTC 113-2314-B-006-090"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","award":["NCKUH-11303051"],"award-info":[{"award-number":["NCKUH-11303051"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","award":["NCKUH-11404024"],"award-info":[{"award-number":["NCKUH-11404024"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-025-01515-6","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T01:15:12Z","timestamp":1741223712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Optimizing bone health with bisphosphonate therapies in pediatric osteogenesis imperfecta: a network meta-analysis of randomized trials"],"prefix":"10.1007","volume":"20","author":[{"given":"Ying-Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Yin","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Che","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Wei","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Fan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ju","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chii-Jeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Chuan","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Lan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Kai","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ren","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Tung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-An","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"crossref","unstructured":"Shih CA, Li CC, Chang YF, et al. (2024) Demographics and medical burden of osteogenesis imperfecta: a nationwide database analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 35:1185-1193","DOI":"10.1007\/s00198-024-07051-2"},{"key":"1515_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10216","volume":"3","author":"CS Constantino","year":"2019","unstructured":"Constantino CS, Krzak JJ, Fial AV, Kruger KM, Rammer JR, Radmanovic K, Smith PA, Harris GF (2019) Effect of bisphosphonates on function and mobility among children with osteogenesis imperfecta: a systematic review. JBMR Plus 3:e10216","journal-title":"JBMR Plus"},{"key":"1515_CR3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/os.12611","volume":"12","author":"Z-m Ying","year":"2020","unstructured":"Ying Z-m, Hu B, Yan S-g (2020) Oral bisphosphonate therapy for osteogenesis imperfecta: a systematic review and meta-analysis of six randomized placebo-controlled trials. Orthop Surg 12:1293\u20131303","journal-title":"Orthop Surg"},{"key":"1515_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00431-006-0399-2","volume":"166","author":"DH Kok","year":"2007","unstructured":"Kok DH, Sakkers RJ, Janse AJ, Pruijs HE, Verbout AJ, Castelein RM, Engelbert RH (2007) Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial. Eur J Pediatr 166:1155\u20131161","journal-title":"Eur J Pediatr"},{"key":"1515_CR5","doi-asserted-by":"crossref","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D (2016) Bisphosphonate therapy for osteogenesis imperfecta. The Cochrane database of systematic reviews 10:Cd005088","DOI":"10.1002\/14651858.CD005088.pub4"},{"key":"1515_CR6","doi-asserted-by":"publisher","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","volume":"23","author":"CG Shi","year":"2016","unstructured":"Shi CG, Zhang Y, Yuan W (2016) Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis. Am J Ther 23:e894-904","journal-title":"Am J Ther"},{"key":"1515_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2174\/1574884713666180829143927","volume":"13","author":"K Sridharan","year":"2018","unstructured":"Sridharan K, Sivaramakrishnan G (2018) Interventions for improving bone mineral density and reducing fracture risk in osteogenesis imperfecta: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials. Curr Clin Pharmacol 13:190\u2013198","journal-title":"Curr Clin Pharmacol"},{"key":"1515_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","volume":"51","author":"H Castillo","year":"2009","unstructured":"Castillo H, Samson-Fang L (2009) Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 51:17\u201329","journal-title":"Dev Med Child Neurol"},{"key":"1515_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","volume":"25","author":"MG Seikaly","year":"2005","unstructured":"Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA (2005) Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25:786\u2013791","journal-title":"J Pediatr Orthop"},{"key":"1515_CR10","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMct1004903","volume":"363","author":"MJ Favus","year":"2010","unstructured":"Favus MJ (2010) Bisphosphonates for osteoporosis. N Engl J Med 363:2027\u20132035","journal-title":"N Engl J Med"},{"key":"1515_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000381713","volume":"84","author":"EBG Rijks","year":"2015","unstructured":"Rijks EBG, Bongers BC, Vlemmix MJG, Boot AM, van Dijk ATH, Sakkers RJB, van Brussel M (2015) Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review. Hormone Research in Paediatrics 84:26\u201342","journal-title":"Hormone Research in Paediatrics"},{"key":"1515_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1515\/jpem-2012-0016","volume":"25","author":"ER Barros","year":"2012","unstructured":"Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M (2012) Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of pediatric endocrinology & metabolism\u202f: JPEM 25:485\u2013491","journal-title":"Journal of pediatric endocrinology & metabolism : JPEM"},{"key":"1515_CR13","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","volume":"382","author":"N Bishop","year":"2013","unstructured":"Bishop N, Adami S, Ahmed SF et al (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet (London, England) 382:1424\u20131432","journal-title":"Lancet (London, England)"},{"key":"1515_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/s40064-015-1474-9","volume":"4","author":"A Horikawa","year":"2015","unstructured":"Horikawa A, Miyakoshi N, Shimada Y, Sugimura Y, Kodama H (2015) A comparative study between intravenous and oral alendronate administration for the treatment of osteoporosis. Springerplus 4:675","journal-title":"Springerplus"},{"key":"1515_CR15","doi-asserted-by":"crossref","unstructured":"Kim HW, Lee MW, Lee JH, Kim MY (2021) Comparison of the effect of oral versus intravenous bisphosphonate administration on osteoclastogenesis in advanced-stage medication-related osteonecrosis of the jaw patients. J Clin Med 10:","DOI":"10.3390\/jcm10132988"},{"key":"1515_CR16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1359\/jbmr.090213","volume":"24","author":"F Rauch","year":"2009","unstructured":"Rauch F, Munns CF, Land C, Cheung M, Glorieux FH (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. Journal of bone and mineral research\u202f: the official journal of the American Society for Bone and Mineral Research 24:1282\u20131289","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"key":"1515_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1210\/jc.2010-0636","volume":"96","author":"LM Ward","year":"2011","unstructured":"Ward LM, Rauch F, Whyte MP et al (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96:355\u2013364","journal-title":"J Clin Endocrinol Metab"},{"key":"1515_CR18","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet (London, England) 363:1427\u20131431","journal-title":"Lancet (London, England)"},{"key":"1515_CR19","doi-asserted-by":"crossref","unstructured":"Marini JC, Forlino A, B\u00e4chinger HP, et al. (2017) Osteogenesis imperfecta. Nature Reviews Disease Primers 3:17052","DOI":"10.1038\/nrdp.2017.52"},{"key":"1515_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jbmr.2410","volume":"30","author":"JD Hald","year":"2015","unstructured":"Hald JD, Evangelou E, Langdahl BL, Ralston SH (2015) Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res 30:929\u2013933","journal-title":"J Bone Miner Res"},{"key":"1515_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4158\/EP171910.OR","volume":"24","author":"F Lv","year":"2018","unstructured":"Lv F, Liu Y, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X, Li M (2018) Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study. Endocr Pract 24:179\u2013188","journal-title":"Endocr Pract"},{"key":"1515_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784","journal-title":"Ann Intern Med"},{"key":"1515_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13643-023-02217-1","volume":"12","author":"KY Chi","year":"2023","unstructured":"Chi KY, Li MY, Chen C, Kang E (2023) Ten circumstances and solutions for finding the sample mean and standard deviation for meta-analysis. Syst Rev 12:62","journal-title":"Syst Rev"},{"key":"1515_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"1515_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5630","volume":"349","author":"MA Puhan","year":"2014","unstructured":"Puhan MA, Sch\u00fcnemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Kessels AG, Guyatt GH (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ\u202f: British Medical Journal 349:g5630","journal-title":"BMJ : British Medical Journal"},{"key":"1515_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE (2013) Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33:641\u2013656","journal-title":"Med Decis Making"},{"key":"1515_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JP (2012) Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 3:111\u2013125","journal-title":"Res Synth Methods"},{"key":"1515_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bone.2019.01.003","volume":"121","author":"N Nasomyont","year":"2019","unstructured":"Nasomyont N, Hornung LN, Gordon CM, Wasserman H (2019) Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review. Bone 121:60\u201367","journal-title":"Bone"},{"key":"1515_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/pr.2015.230","volume":"79","author":"EL Germain-Lee","year":"2016","unstructured":"Germain-Lee EL, Brennen F-S, Stern D, Kantipuly A, Melvin P, Terkowitz MS, Shapiro JR (2016) Cross-sectional and longitudinal growth patterns in osteogenesis imperfecta: implications for clinical care. Pediatr Res 79:489\u2013495","journal-title":"Pediatr Res"},{"key":"1515_CR30","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41436-018-0307-y","volume":"21","author":"LA Barber","year":"2019","unstructured":"Barber LA, Abbott C, Nakhate V, Do AND, Blissett AR, Marini JC (2019) Longitudinal growth curves for children with classical osteogenesis imperfecta (types III and IV) caused by structural pathogenic variants in type I collagen. Genet Med 21:1233\u20131239","journal-title":"Genet Med"},{"key":"1515_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10118","volume":"3","author":"JS Bains","year":"2019","unstructured":"Bains JS, Carter EM, Citron KP et al (2019) A multicenter observational cohort study to evaluate the effects of bisphosphonate exposure on bone mineral density and other health outcomes in osteogenesis imperfecta. JBMR plus 3:e10118","journal-title":"JBMR plus"},{"key":"1515_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097218","volume":"9","author":"P Nakavachara","year":"2014","unstructured":"Nakavachara P, Pooliam J, Weerakulwattana L, Kiattisakthavee P, Chaichanwattanakul K, Manorompatarasarn R, Chokephaibulkit K, Viprakasit V (2014) A normal reference of bone mineral density (BMD) measured by dual energy X-ray absorptiometry in healthy thai children and adolescents aged 5\u201318 years: a new reference for Southeast Asian Populations. PLoS ONE 9:e97218","journal-title":"PLoS ONE"},{"key":"1515_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163\u2013171","journal-title":"J Clin Epidemiol"},{"key":"1515_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1359\/JBMR.051006","volume":"21","author":"LA DiMeglio","year":"2006","unstructured":"DiMeglio LA, Peacock M (2006) Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21:132\u2013140","journal-title":"J Bone Miner Res"},{"key":"1515_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4158\/EP171910.OR","volume":"24","author":"F Lv","year":"2018","unstructured":"Lv F, Liu Y, Xu X, Song Y, Li L, Jiang Y, Wang O, Xia W, Xing X (2018) Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study. Endocr Pract 24:179\u2013188","journal-title":"Endocr Pract"},{"key":"1515_CR36","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","volume":"27","author":"P Trejo","year":"2016","unstructured":"Trejo P, Rauch F (2016) Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporos Int 27:3427\u20133437","journal-title":"Osteoporos Int"},{"key":"1515_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1359\/jbmr.090712","volume":"25","author":"N Bishop","year":"2010","unstructured":"Bishop N, Harrison R, Ahmed F et al (2010) A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of bone and mineral research\u202f: the official journal of the American Society for Bone and Mineral Research 25:32\u201340","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"key":"1515_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00247-006-0153-y","volume":"37","author":"LA Binkovitz","year":"2007","unstructured":"Binkovitz LA, Henwood MJ (2007) Pediatric DXA: technique and interpretation. Pediatr Radiol 37:21\u201331","journal-title":"Pediatr Radiol"},{"key":"1515_CR39","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1002\/jbmr.3833","volume":"34","author":"ME Robinson","year":"2019","unstructured":"Robinson ME, Trejo P, Palomo T, Glorieux FH, Rauch F (2019) Osteogenesis imperfecta: skeletal outcomes after bisphosphonate discontinuation at final height. J Bone Miner Res 34:2198\u20132204","journal-title":"J Bone Miner Res"},{"key":"1515_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jbspin.2018.02.009","volume":"85","author":"K Briot","year":"2018","unstructured":"Briot K, Roux C, Thomas T et al (2018) 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine 85:519\u2013530","journal-title":"Joint Bone Spine"},{"key":"1515_CR41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.semarthrit.2008.04.001","volume":"38","author":"A Mounach","year":"2009","unstructured":"Mounach A, Abayi DA, Ghazi M, Ghozlani I, Nouijai A, Achemlal L, Bezza A, El Maghraoui A (2009) Discordance between hip and spine bone mineral density measurement using DXA: prevalence and risk factors. Semin Arthritis Rheum 38:467\u2013471","journal-title":"Semin Arthritis Rheum"},{"key":"1515_CR42","first-page":"341","volume":"35","author":"PJ Phillips","year":"2006","unstructured":"Phillips PJ, Phillipov G (2006) Bone mineral density - frequently asked questions. Aust Fam Physician 35:341\u2013344","journal-title":"Aust Fam Physician"},{"key":"1515_CR43","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1359\/JBMR.050109","volume":"20","author":"AD Letocha","year":"2005","unstructured":"Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977\u2013986","journal-title":"J Bone Miner Res"},{"key":"1515_CR44","first-page":"1846","volume":"85","author":"H Plotkin","year":"2000","unstructured":"Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age*. J Clin Endocrinol Metab 85:1846\u20131850","journal-title":"J Clin Endocrinol Metab"},{"key":"1515_CR45","doi-asserted-by":"crossref","unstructured":"Powell DE, Evans SF, Rakieh C (2023) Bone mineral density response to long-term bisphosphonate treatment and discontinuation in a real-world clinical service. endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 29:601\u2013605","DOI":"10.1016\/j.eprac.2023.04.011"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-025-01515-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:16:37Z","timestamp":1766524597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-025-01515-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1007\/s11657-025-01515-6","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient involvement statement"}}],"article-number":"33"}}